Whether your lab is researching and developing targeted cancer therapies or you are analyzing and interpreting diagnostic tests at the point-of-care, a critical part of your workflow is understanding the structural and functional impact of cancer-related mutations. 

The Catalogue Of Somatic Mutations In Cancer (COSMIC) is an expert-curated database encompassing a wide variety of somatic mutation mechanisms causing human cancer. Containing more than 24 million somatic variants with detailed information on mutation distribution, effects, and signatures, COSMIC helps users better predict the cancer-driving effects of mutations and identify available drugs that target specific variants. COSMIC continues to expand its utility with continuous updates to its Mutational Signatures, the Cancer Mutation Census, and Mutation Actionability in Precision Oncology products.

To illustrate key applications of these features, this webinar will focus on how COSMIC can be used to avoid mutational consequences in cancer drug development and to profile the mutational signatures of cancer therapies in clinical samples.

 

Through these clinical and discovery use cases, attendees will learn:

  • How to evaluate genomic loci using the comprehensive coding and non-coding variant annotations within COSMIC
  • How to integrate these variants with curated findings and summaries of mutational impact and clinical actionability
  • How mutational signatures could be useful for clinical diagnosis and drug development applications now and in the future

 

About the speaker
Kyle Nilson, PhD, Field Software Trainer
QIAGEN Digital Insights (QDI)
Kyle Nilson, Ph.D. is a sequencing-focused molecular biologist with a background in biochemistry and technical support. As a field software trainer at QIAGEN Digital Insights, Dr. Nilson works closely with QIAGEN’s global bioinformatics team to provide direct customer support and assits with software training, implementation, and optimization. He received his Ph.D. in molecular and cellular biology from the University of Iowa, studying the regulation of RNA polymerase II transcription and co-transcriptional mRNA processing. Dr. Nilson went on to complete his postdoctoral training at Penn State and Cornell University, where he focused exclusively on next-generation sequencing method development to study chromatin.
Steven Jupe, PhD, Principal Curator for COSMIC Actionability
Wellcome Sanger Institute
Steve joined COSMIC as the Principal Curator for Actionability in 2018. His extensive career in biology and bioinformatics includes 7 years as a postdoctoral molecular biologist, 13 years in the bioinformatics group at GlaxoSmithKline (GSK), and 9 years curating biological pathways for the Reactome project at EMBL-EBI.
Date of recording:Thursday, 7 March 2024
Duration:60 minutes
Categories
Webinar
Pharma / Biopharma
Drug Discovery
Bioinformatics
Oncology